FMP
Unicycive Therapeutics, Inc.
UNCY
NASDAQ
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
1.04 USD
-0.03 (-2.88%)
About
ceo
Dr. Shalabh K. Gupta M.D., MPA
sector
Healthcare
industry
Biotechnology
website
https://www.unicycive.com
exchange
NASDAQ
Description
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
CIK
0001766140
ISIN
US90466Y1038
CUSIP
90466Y103
Address
4300 El Camino Real
Phone
650 351 4495
Country
US
Employee
14
IPO Date
Jul 12, 2021
Summary
CIK
0001766140
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
90466Y103
ISIN
US90466Y1038
Country
US
Price
1.04
Beta
2.65
Volume Avg.
375.97k
Market Cap
36.15M
Shares
-
52-Week
0.47-1.823
DCF
0.39
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.81
P/B
-
Website
https://www.unicycive.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest UNCY News
It looks like there's no news available.
